| Symbol | ERBB |
|---|---|
| Name | AMERICAN GREEN, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 82801 United States WY 30 N Gould Street Suite R Suite R |
| Telephone | 480-443-1600 |
| Fax | — |
| — | |
| Website | http://www.americangreen.com |
| Incorporation | US |
| Incorporated On | 2016 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001122973 |
| Description | American Green, Inc. is second oldest publicly-traded cannabis company in America, with over 50,000 certified shareholders as of Dec 31, 2018.. The Company is focused on leading-edge cannabis-industry solutions as seen from a "50,000 foot view." American Green has participated in nearly all facets of the cannabis market. Its current initiatives include (but are not limited to) the expansion of managed state-of-the-art cultivation facility in Arizona (Q2/20), the promotion and national sales of non-THC, medically-focused CBD (Cannabidiol) products from both whole plant and organic hemp sources, the development and rollout of a very smart automated vending solution system called AGM - a vending machine designed to electronically and physically identify, in advance of a sale, individuals wishing to purchase "adult-only or controlled products that include beer, wine and other alcoholic beverages in casinos, hotels, and sports stadiums. Since the companys home state of Arizona recently passed a law permitting the recreational use of cannabis beginning in 2021, American Green sees the continuing legalization of cannabis across the US as an opportunity to exploit the companys capabilities, experience, and future income opportunities. Additional info from OTC: |
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Read moreReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Read moreReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Read moreReviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
Read more